blend80MG
KLOW
80MG Protocol
KLOW 80MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
Accelerated tissue repair and wound healing (multi‑pathway)
Reduced inflammation via cytokine modulation / NF‑κB inhibition
Enhanced collagen/connective‑tissue support (GHK‑Cu)
Promotes angiogenesis and improved blood flow to healing tissue
Supports musculoskeletal recovery and joint health
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 |
| 2 | Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 |
| 3 | Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 |
| 4 | Weeks 9–12 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 |
Inject once daily
8–12 weeks; optional extension to 16 weeks
KLOW is positioned as a multi‑pathway repair and ‘skin/soft‑tissue remodeling’ blend. It combines TB‑500 (thymosin β4) to support cell migration and angiogenesis; BPC‑157 to support repair signaling across tendon/ligament/muscle and to modulate growth‑factor pathways; KPV to help down‑shift inflammatory tone through NF‑κB inhibition; and GHK‑Cu to support extracellular‑matrix remodeling by stimulating collagen/elastin synthesis and modulating gene expression tied to tissue renewal. Rather than focusing on a single receptor, the protocol’s rationale is systems‑level: improve local blood‑flow signals (angiogenesis), support the cellular ‘scaffolding’ and migration needed for closure and remodeling, and reduce inflammatory cytokine signaling that can stall repair. The combined effect is framed as faster healing plus better connective‑tissue quality—useful where injury, inflammation, and collagen remodeling all matter simultaneously.
Mild injection‑site redness/irritation
Occasional lightheadedness (reported
possibly vasodilatory)
Limited human clinical data (most evidence preclinical)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)